News
More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...
Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...
Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...
9d
Investor's Business Daily on MSNWhy S&P 500 Stock Amgen Stumbled Despite Its Beat-And-Raise Quarter
Amgen stock dropped Wednesday despite a strong second quarter as investors look ahead to the next weight-loss readouts.
Thousand Oaks-based Amgen saw shares dip about 5% on Aug. 6, the day after the company’s earnings announcement, though not because of the earnings themselves but rather about news of its weight-loss ...
Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...
For the second quarter, total revenues increased 9% to $9.2 billion in comparison to the second quarter of 2024. Product sales grew 9%, driven by 13% volume g ...
Amgen’s diversified portfolio strategy continues to hinge on a balance between high-margin legacy biologics, expanding biosimilar offerings, and innovative pipeline investments. Repatha and BLINCYTO ...
The biotech heavyweight reported adjusted earnings per share of $6.02 for the second quarter, well above the $5.26 anticipated by Wall Street analysts. Revenue climbed 9% from the prior year to $9.18 ...
Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook amid patent expiries & sector issues.
Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that obesity is a problem at all.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results